PFIZER · Healthcare · Drug Manufacturers - General
Composite scorecard: 77/100 — Quality 89 · Momentum 49
| Share price | ₹4,577.90 |
| Market cap | ₹23,158 Cr |
| P/E ratio | 27.1 |
| P/B ratio | 6.0 |
| ROE | 30.9% |
| ROCE | 23.6% |
| Dividend yield | 0.69% |
| Book value | ₹841.24 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2025 | ₹2,281 Cr | ₹768 Cr | 29.9% |
| 2024 | ₹2,193 Cr | ₹551 Cr | 26.3% |
| 2023 | ₹2,422 Cr | ₹624 Cr | 29.3% |
| 2022 | ₹2,611 Cr | ₹613 Cr | 27.6% |
| 2021 | — | — | — |
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was